University of Eastern Finland, A.I. Virtanen institute, Department of Biotechnology and Molecular Medicine, Kuopio, Finland.
Expert Opin Drug Deliv. 2010 May;7(5):551-64. doi: 10.1517/17425241003677749.
The goal of drug targeting is to increase the concentration of the drug in the vicinity of the cells responsible for disease without affecting healthy cells. Many approaches in cancer treatment are limited because of their broad range of unwanted side effects on healthy cells. Targeting can reduce side effects and increase efficacy of drugs in the patient.
Avidin, originally isolated from chicken eggs, and its bacterial analogue, streptavidin, from Streptomyces avidinii, have extremely high affinity for biotin. This unique feature is the basis of avidin-biotin technology. This article reviews the current status of avidin-biotin systems and their use for pretargeted drug delivery and vector targeting.
The reader will gain an understanding of the following approaches using the avidin-biotin system: i) targeting antibodies and therapeutic molecules are administered separately leading to a reduction of drug dose in normal tissues compared with conventional (radio)immunotherapies; ii) introducing avidin gene into specific tissues by local gene transfer, which subsequently can sequester and concentrate considerable amounts of therapeutic ligands; and iii) enabling transductional targeting of gene therapy vectors.
Avidin and biotin technology has proved to be an extremely versatile tool with broad applications, such as pretargeting, delivering avidin gene into cells enabling targeting of biotinylated compounds and targeting of viral vectors.
药物靶向的目标是增加药物在负责疾病的细胞附近的浓度,而不影响健康细胞。许多癌症治疗方法都受到限制,因为它们对健康细胞有广泛的不必要的副作用。靶向治疗可以减少副作用,并提高患者的药物疗效。
亲和素有两种,一种来自鸡卵,另一种来自链霉菌属的链霉亲和素,它们对生物素有极高的亲和力。这种独特的特性是亲和素-生物素技术的基础。本文综述了亲和素-生物素系统的现状及其在预靶向药物传递和载体靶向中的应用。
i)单独给予靶向抗体和治疗分子,与传统(放射性)免疫疗法相比,可减少正常组织中的药物剂量;ii)通过局部基因转移将亲和素基因引入特定组织,随后可隔离和浓缩大量治疗配体;iii)使基因治疗载体能够进行转导性靶向。
亲和素有两种,一种来自鸡卵,另一种来自链霉菌属的链霉亲和素,它们对生物素有极高的亲和力。这种独特的特性是亲和素-生物素技术的基础。本文综述了亲和素-生物素系统的现状及其在预靶向药物传递和载体靶向中的应用。
i)单独给予靶向抗体和治疗分子,与传统(放射性)免疫疗法相比,可减少正常组织中的药物剂量;ii)通过局部基因转移将亲和素基因引入特定组织,随后可隔离和浓缩大量治疗配体;iii)使基因治疗载体能够进行转导性靶向。